Rezolute Q2 FY2023 net loss $13.6M; cash $146.7M; Phase 2 DME study initiated

Rezolute, Inc.

2023-Q2 EPS reported -$0.46

Net loss $13.6M for Q2 FY2023 ended Dec 31, 2022 vs $12.6M same period prior year.
Cash and cash equivalents $146.7M as of Dec 31, 2022.
R&D expenses $10.9M, G&A expenses $3.4M, both up on higher compensation and headcount.
Initiated Phase 2 proof-of-concept study for RZ402 in diabetic macular edema in Dec 2022.
Anticipates initiating global Phase 3 study for RZ358 in congenital hyperinsulinism mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Rezolute, Inc. reported financial results for second quarter of fiscal 2023 ended December 31, 2022.

Period: second quarter of fiscal 2023 ended December 31, 2022
Result: reported results

Exact text from the filing

On February 10, 2023, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-018522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.